ArticlePloS one2016
The Formulation of Bacteriophage in a Semi Solid Preparation for Control of Propionibacterium acnes Growth.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 73 citations in OpenAlex.
- Spot-on phage therapy: stable formulations, smarter dosing for topical phage application.Frontiers in cellular and infection microbiology · 2026Review
- Genomic characterization and pre-clinical evaluation of a new polyvalent lytic Loughborough phage.Applied microbiology and biotechnology · 2025Article
- In vitro, genomic characterization and pre-clinical evaluation of a new thermostable lytic Obolenskvirus phage formulated as a hydrogel against carbapenem-resistant Acinetobacter baumannii.Scientific reports · 2025Article
- Antibacterial activity and impact on keratinocyte cell growth ofCurrent research in microbial sciences · 2025Article
- Cutibacterium acnes bacteriophage therapy: exploring a new frontier in acne vulgaris treatment.Archives of dermatological research · 2024Review
- Bacteriophage entrapment strategies for the treatment of chronic wound infections: a comprehensive review.Archives of microbiology · 2024Review
- Application of bacteriophage φPaP11-13 attenuates ratMicrobiology spectrum · 2024Article
- Expression of a recombinant endolysin from bacteriophage CAP 10-3 with lytic activity against Cutibacterium acnes.Scientific reports · 2023Article
- Targeting Inflammation in Acne: Current Treatments and Future Prospects.American journal of clinical dermatology · 2023Article
- Article
- Article
- Characterization and Engineering Studies of a New Endolysin from theInternational journal of molecular sciences · 2023Article
- Bacteriophages and the Microbiome in Dermatology: The Role of the Phageome and a Potential Therapeutic Strategy.International journal of molecular sciences · 2023Review
- Microbiome and Human Health: Current Understanding, Engineering, and Enabling Technologies.Chemical reviews · 2023Review
- Current Status of Phage Therapy against Infectious Diseases and Potential Application beyond Infectious Diseases.International journal of clinical practice · 2022Review
- Microbiome therapeutics: exploring the present scenario and challenges.Gastroenterology report · 2022Review
- A Journey on the Skin Microbiome: Pitfalls and Opportunities.International journal of molecular sciences · 2021Review
- Manufacturing Bacteriophages (Part 2 of 2): Formulation, Analytics and Quality Control Considerations.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Wastewater as a fertility source for novel bacteriophages against multi-drug resistant bacteria.Saudi journal of biological sciences · 2021Review
- Therapeutic Effect of a Newly Isolated Lytic Bacteriophage against Multi-Drug-ResistantInternational journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo isolate and characterise phage which could lyse P. acnes and to formulate the phage into a delivery form for potential application in topical treatment of acne infection. METHODS AND
resultsUsing standard phage isolation techniques, ten phage capable of lysing P. acnes were isolated from human skin microflora. Their genomes showed high homology to previously reported P. acnes phage. These phage were formulated into cetomacrogol cream aqueous at a concentration of 2.5x108 PFU per gram, and shown to lyse underlying P. acnes cells grown as lawn cultures. These phage formulations remained active for at least 90 days when stored at four degrees Celsius in a light protected container.
conclusionsP. acnes phage formulated into cetomacrogol cream aqueous will lyse surrounding and underlying P. acnes bacteria, and are effective for at least 90 days if stored appropriately. SIGNIFICANCE AND IMPACT OF THE STUDY: There are few reports of phage formulation into semi solid preparations for application as phage therapy. The formulation method described here could potentially be applied topically to treat human acne infections. The potential exists for this model to be extended to other phage applied to treat other bacterial skin infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.